In the study of Centonze et al., [88] they reveal a novel mechanism through which metastatic colorectal cancer (mCRC) develops resistance to KRAS–G12D inhibitors: tumor cells rapidly undergo plastic conversion from an EMP1+ non‐stem cell state to an Lgr5+ stem‐like state to evade drug treatment. Here, KRAS is linked to neoplasm.